NCT04712201

Brief Summary

INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. The current standard is based on conventional transurethral resection of bladder tumor, although high rates of recurrence have been reported following resection of the primary tumor. Given the importance of a correct initial diagnosis in these cases, en bloc transurethral resection has developed over the past 2 decades. This technique was born, according to the literature, with 3 main objectives: to improve the quality of the surgical piece for its anatomopathological reading, reduce the rate of postoperative complications and reduce the rate of relapses in the surgical bed. This technique is used as a common practice of tumor resection in other centers and has been shown in multiple publications that it does not increase surgical risk or negatively affect cancer results. OBJECTIVE The objective of our study is to compare feasibility, perioperative complication rate, accuracy of staging and recurrence/progression rates when performing en bloc resection by means of different energies: monopolar, bipolar and laser energy. MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be conducted including patients undergoing a transurethral resection of initial or recurrent bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote metastasis, whether lymphatic or organic, will be excluded. Patients will be randomized into two groups:

  • Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according to the energy used (monopolar, bipolar, laser energy).
  • Group 2 (control): Conventional transurethral resection (n-120). It will be divided into 2 subgroups depending on the energy used (monopolar or bipolar). A fact sheet will be given to the patient about the study and the signature of the informed consent will be requested in order to be included. The patient will be free to leave the study at any time without having to provide any justification and without affecting the treatment, intervention and follow-up that must be carried out. The processing and storage of samples will be carried out in the pathological anatomy laboratory, according to standard clinical practice. Patients will be monitored according to the usual clinical practice protocol (minimum 5-year follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert Foundation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

January 12, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 15, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
4.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

January 15, 2021

Status Verified

January 1, 2021

Enrollment Period

3.2 years

First QC Date

January 12, 2021

Last Update Submit

January 13, 2021

Conditions

Keywords

TURBTEn blocUrothelial cancer

Outcome Measures

Primary Outcomes (1)

  • Staging of bladder tumor

    Evaluation of muscle presence in the specimen

    Three years

Secondary Outcomes (8)

  • Intraoperative complications

    Three years

  • Rate of planned adjuvant treatment

    Three years

  • Post-operative complications

    Three years

  • Substaging T1 bladder cancer

    Three years

  • Recurrence-free survival

    Through study completion, an average of five years

  • +3 more secondary outcomes

Study Arms (2)

En bloc

EXPERIMENTAL

En bloc transurethral resection of the bladder

Procedure: En bloc transurethral resection of bladder tumor (TURBT)

Conventional

ACTIVE COMPARATOR

Conventional transurethral resection of the bladder

Procedure: Conventional TURBT

Interventions

En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy

En bloc

Conventional transurethral resection of bladder tumor using monopolar and bipolar energy

Conventional

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
  • Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm

You may not qualify if:

  • Evidence of \> 3 tumors or \> 3 cm
  • Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
  • Computed tomography/magnetic resonance evidence of distant metastases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fundacio Puigvert

Barcelona, 08025, Spain

RECRUITING

Related Publications (1)

  • Gallioli A, Diana P, Fontana M, Territo A, Rodriguez-Faba O, Gaya JM, Sanguedolce F, Huguet J, Mercade A, Piana A, Aumatell J, Bravo-Balado A, Algaba F, Palou J, Breda A. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022 Aug;5(4):440-448. doi: 10.1016/j.euo.2022.05.001. Epub 2022 May 23.

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of the Uro-Oncology Division and Kidney Transplant Unit

Study Record Dates

First Submitted

January 12, 2021

First Posted

January 15, 2021

Study Start

April 1, 2018

Primary Completion

June 1, 2021

Study Completion

April 1, 2026

Last Updated

January 15, 2021

Record last verified: 2021-01

Locations